 Just a day after European approval, Albireo Pharma Inc NASDAQ: ALBO has received FDA approval for Bylvay odevixibat, the first drug approved to treat pruritus in all subtypes of progressive familial intrahepatic cholestasis PFIC. PFIC afflicts children with severe, progressive liver disease. 